An update on the pharmacological management of female sexual dysfunction

Bibliography

• Tan HM, Marumo K, Yang D-y, Sex among Asian men and women: the global better sex survey in Asia. Int J Urol 2009;16(5):507-14
   PubMed Web of Science ®Google Scholar
• Laumann E, Paik A, Rosen RC. Sexual dysfunction in the United States:prevalence and predictors. JAMA 1999;281:537-44
   PubMed Web of Science ®Google Scholar
• Davison SL, Bell RJ, LaChina M, The Relationship between Self-Reported Sexual Satisfaction and General Well-Being in Women. J Sex Med 2009;6(10):2690-7
   PubMed Web of Science ®Google Scholar
• Basson R. Women's sexual function and dysfunction: current uncertainties, future directions. Int J Impot Res 2008;20(5):466-78
   PubMed Web of Science ®Google Scholar
• Cain VS, Johannes CB, Avis NE, Sexual functioning and practices in a multi-ethnic study of midlife women: baseline results from SWAN. J Sex Res 2003;40(3):266-76
   PubMed Web of Science ®Google Scholar
• Beckman N, Waern M, Gustafson D, Secular trends in self reported sexual activity and satisfaction in Swedish 70 year olds: cross sectional survey of four populations, 1971-2001. BMJ 2008;337:a279
   PubMed Web of Science ®Google Scholar
• Biddle AK, West SL, D'Aloisio AA, Hypoactive Sexual Desire Disorder in Postmenopausal Women: Quality of Life and Health Burden. Value Health 2009;12(5):763-72
   PubMed Web of Science ®Google Scholar
• Williams VS, Baldwin DS, Hogue SL, Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in two European countries: a cross-sectional patient survey. J Clin Psychiatry 2006;67(2):204-10
   PubMedGoogle Scholar
• Davison SL, Bell RJ, LaChina M, The relationship between self-reported sexual satisfaction and general well-being in women. J Sex Med 2009;Oct6(10):2690-7
   PubMed Web of Science ®Google Scholar
• World Health Organization. Sexual health. In: Health topics. WHO; Geneva: 2011
   Google Scholar
• Saks BR, Gillespie MA. Psychotropic medication and sexual function in women: an update. Arch Women Ment Health 2002;4(4):139-44
   Google Scholar
• Basson R, Leiblum S, Brotto L, Definitions of women's sexual dysfunction reconsidered: advocating expansion and revision. J Psychosom Obstet Gynaecol 2003;24(4):221-9
   PubMed Web of Science ®Google Scholar
• Beck JG. Hypoactive Sexual Desire Disorder: an Overview. J Consult Clin Psychol 1995;63(6):919-27
   PubMed Web of Science ®Google Scholar
• Masters WH, Johnson VE. editors. Human sexual response. New York, Bantam Books; Toronto: 1966
   Google Scholar
• Wylie K, Mimoun S. Sexual response models in women. Maturitas 2009;63(2):112-15
   PubMedGoogle Scholar
• Basson R. Women's sexual dysfunction:revised and expanded definitions. Can Med Assoc J 2005;172:1327-33
   PubMed Web of Science ®Google Scholar
• Pfaus JG. Reviews: pathways of sexual desire. J Sex Med 2009;6(6):1506-33
   PubMed Web of Science ®Google Scholar
• Frohlich PF, Meston CM. Evidence that serotonin affects female sexual functioning via peripheral mechanisms. Physiol Behav 2000;71(3–4):383-93
   PubMed Web of Science ®Google Scholar
• Davis SR, Guay AT, Shifren JL, Endocrine Aspects of Female Sexual Dysfunction. J Sex Med 2004;1(1):82-6
   Google Scholar
• Davis SR, van der Mooren MJ, van Lunsen RHW, Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 2006;13(3):387-96
   PubMed Web of Science ®Google Scholar
• Al-Azzawi F, Bitzer J, Brandenburg U, Therapeutic options for postmenopausal female sexual dysfunction. Climacteric 2010;13(2):103-20
   PubMed Web of Science ®Google Scholar
• Shifren JL. The role of androgens in female sexual dysfunction. Mayo Clin Proc 2004;79(4 Suppl):S19-24
   PubMedGoogle Scholar
• Mimoun S, Wylie K. Female sexual dysfunctions:definitions and classification. Maturitas 2009;63:116-18
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association, ed. Diagnostic and statistical manual of mental disorder. American Psychaitric Association; Washington, DC: 2000
   Google Scholar
• Basson R, Berman J, Burnett A, Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 2000;163(3):888-93
   PubMed Web of Science ®Google Scholar
• Shifren JL, Monz BU, Russo PA, Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008;112(5):970-8
   PubMed Web of Science ®Google Scholar
• Hayes RD, Dennerstein L, Bennett CM, What is the "true" prevalence of female sexual dysfunctions and does the way we assess these conditions have an impact? J Sex Med 2008;5(4):777-87
   PubMed Web of Science ®Google Scholar
• Moreira ED, Glasser DB, King R, Sexual difficulties and help-seeking among mature adults in Australia: results from the Global Study of Sexual Attitudes and Behaviours. Sex Health 2008;5(3):227-34
   PubMed Web of Science ®Google Scholar
• Fooladi E, Bell RJ, Davis SR. Management strategies in SSRI-associated sexual dysfunction in women at midlife. Climacteric 2012;15(4):306-16
   PubMed Web of Science ®Google Scholar
• Basson R. Pharmacotherapy for women's sexual dysfunction. Expert Opin Pharmacother 2009;10(10):1631-48
   PubMed Web of Science ®Google Scholar
• Brotto LA, Bitzer J, Lann E, Women's Sexual desire and arousal disorder. J Sex Med 2010;7:586-614
   PubMed Web of Science ®Google Scholar
• Clayton AH. Sexual function and dysfunction in women. Psychiatr Clin North Am 2003;Sep26(3):673-82
   PubMed Web of Science ®Google Scholar
• Da Silva Lara LA, Useche B, Ferriani RA, REVIEWS: the Effects of Hypoestrogenism on the Vaginal Wall: Interference with the Normal Sexual Response. J Sex Med 2009;6(1):30-9
   PubMedGoogle Scholar
• Blakeman PJ, Hilton P, Bulmer JN. Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen status. BJU Int 2000;86(1):32-8
   PubMed Web of Science ®Google Scholar
• Simon JA. Identifying and treating sexual dysfunction in postmenopausal women: the role of estrogen. J Womens Health 2011;20(10):1453-65
   Google Scholar
• Suckling Jane A, Kennedy R, Lethaby A, Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews [Internet]. John Wiley & Sons, Ltd; 2006;4
   Google Scholar
• The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14(3):357-69
   Web of Science ®Google Scholar
• Archer DF, Pickar JH, MacAllister DC, Transdermal estradiol gel for the treatment of symptomatic postmenopausal women. Menopause 2012;19(6):622-9
   PubMedGoogle Scholar
• Panay N, Maamari R. Treatment of postmenopausal vaginal atrophy with 10-mug estradiol vaginal tablets. Menopause Int 2012;Mar18(1):15-19
   PubMedGoogle Scholar
• Chollet JA. Efficacy and safety of ultra-low-dose Vagifem (10 mcg). Patient Prefer Adherence 2011;5:571-4
   PubMed Web of Science ®Google Scholar
• Levine JP. Treating Menopausal Symptoms With a Tissue-Selective Estrogen Complex. Gend Med 2011;8(2):57-68
   PubMedGoogle Scholar
• Labrie F. Intracrinology. Mol Cell Endocrinol 1991;78:C113-C8
   PubMed Web of Science ®Google Scholar
• Taieb J, Mathian B, Millot F, Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 2003;49(8):1381-95
   PubMed Web of Science ®Google Scholar
• Davis SR, Davison SL, Donath S, Circulating androgen levels and self-reported sexual function in women. JAMA 2005;294(1):91-6
   PubMed Web of Science ®Google Scholar
• Leiblum S, Bachmann GA, Kemmann E, The importance of sexual activity and hormones. JAMA 1983;249:2195
   PubMed Web of Science ®Google Scholar
• Worboys S, Kotsopoulos D, Teede H, Parental testosterone improves endothelium-dependent and independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab 2001;86(1):158-61
   PubMed Web of Science ®Google Scholar
• Tuiten A, Von Honk J, Koppeschaar H, Time course of effects of testosterone administration on sexual arousal in women. Arch Gen Psychiatry 2000;57:149
   PubMed Web of Science ®Google Scholar
• Harada N, Sasano H, Murakami H, Localized expression of aromatase in human vascular tissues. Circ Res 1999;84(11):1285-91
   PubMedGoogle Scholar
• Davison SL, Bell R, Donath S, Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90(7):3847-53
   PubMed Web of Science ®Google Scholar
• Judd HL. Hormonal dynamics associated with the menopause. Clin Obstet Gynecol 1976;19(4):775-88
   PubMedGoogle Scholar
• Hughes CL Jr, Wall LL, Creasman WT. Reproductive hormone levels in gynecologic oncology patients undergoing surgical castration after spontaneous menopause. Gynecol Oncol 1991;40(1):42-5
   PubMedGoogle Scholar
• Mathur RS, Landgrebe SC, Moody LO, The effect of estrogen treatment on plasma concentrations of steroid hormones, gonadotropins, prolactin and sex hormone-binding globulin in post-menopausal women. Maturitas 1985;7(2):129-33
   PubMedGoogle Scholar
• Davis SR, McCloud PI, Strauss BJG, Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227-36
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Bancroft J, Braunstein G, Female androgen insufficiency: the Princeton Consensus Statement on definition, classification and assessment. Fertil Steril 2002;200277(660):665
   Google Scholar
• Burger HG. Androgen production in women. Fertil Steril 2002;77(Suppl 4):S3
   PubMed Web of Science ®Google Scholar
• Panay N, Al-Azzawi F, Bouchard C, Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric 2010;13(2):121-31
   PubMed Web of Science ®Google Scholar
• Simon J, Braunstein G, Nachtigall L, Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90(9):5226-33
   PubMed Web of Science ®Google Scholar
• Shifren J, Davis SR, Moreau M, Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 study. Menopause 2006;13(5):770-9
   PubMed Web of Science ®Google Scholar
• Davis SR, Moreau M, Kroll R, Testosterone for Low Libido in Menopausal Women Not Taking Estrogen Therapy. N Eng J Med 2008;359(6):2005-17
   PubMedGoogle Scholar
• Somboonporn W, Davis SR, Bell RJ. Testosterone for peri and postmenopausal women. Cochrane Database of Systematic Reviews [Internet] 2005;4
   Google Scholar
• Miller KK, Biller BM, Beauregard C, Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2006;91(5):1683-90
   PubMed Web of Science ®Google Scholar
• Goldstat R, Briganti E, Tran J, Transdermal testosterone improves mood, well being and sexual function in premenopausal women. Menopause 2003;10(5):390-8
   PubMed Web of Science ®Google Scholar
• Davis SR, Papalia MA, Norman RJ, Safety and Efficacy of a Testosterone Metered-Dose Transdermal Spray for treatment of decreased sexual satisfaction in Premenopausal Women: a Placebo-Controlled Randomized, Dose-Ranging Study. Annals Internal Med 2008;148:569-77
   PubMed Web of Science ®Google Scholar
• El-Hage G, Eden JA, Zoa Manga R. A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. Climacteric 2007;10(4):335-43
   PubMed Web of Science ®Google Scholar
• Singh AB, Lee ML, Sinha-Hikim I, Pharmacokinetics of a Testosterone Gel in Healthy Postmenopausal Women. J Clin Endocrinol Metab 2006;91(1):136-44
   PubMedGoogle Scholar
• White WB, Grady D, Giudice LC, A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder. Am Heart J 2012;163(1):27-32
   PubMed Web of Science ®Google Scholar
• Davis SR. Androgen Replacement in Women: a Commentary. J Clin Endocrinol Metab 1999;84(6):1886
   PubMed Web of Science ®Google Scholar
• Sarrel P, Dobay B, Wiita B. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses. Journal of Reproductive Medicine 1998;43(10):847-56
   PubMed Web of Science ®Google Scholar
• Warnock JK, Swanson SG, Borel RW, Combined esterified estrogens and methyltestosterone versus esterified estrogens alone in the treatment of loss of sexual interest in surgically menopausal women. Menopause 2005;12(4):374-84
   PubMedGoogle Scholar
• Lobo R, Rosen RC, Yang H-M, Comparative effects of oral esterified estrogens with and without methyl testosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003;79:1341-52
   PubMed Web of Science ®Google Scholar
• Leao LM, Duarte MP, Silva DM, Influence of methyltestosterone postmenopausal therapy on plasma lipids, inflammatory factors, glucose metabolism and visceral fat: a randomized study. Eur J Endocrinol 2006;154(1):131-9
   PubMedGoogle Scholar
• Buckler HM, Robertson WR, Wu FCW. Which Androgen Replacement Therapy for Women?*. J Clin Endocrinol Metab 1998;83(11):3920
   PubMedGoogle Scholar
• Witherby S, Johnson J, Demers L, Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist 2011;16(4):424-31
   PubMed Web of Science ®Google Scholar
• Davis SR, Goldstat R, Papalia MA, Effects of aromatase inhibition on sexual function and wellbeing in postmenopausal women treated with testosterone: a randomized placebo controlled trial. Menopause 2006;13(1):37-45
   PubMedGoogle Scholar
• Davis SR, Braunstein GD. Efficacy and Safety of Testosterone in the Management of Hypoactive Sexual Desire Disorder in Postmenopausal Women. The Journal of Sexual Medicine 2012;9(4):1134-48
   PubMedGoogle Scholar
• Nijland EA, Schultz WCMW, Nathorst-Boos J, ORIGINAL RESEARCH—FSD PHARMACOTHERAPY: tibolone and Transdermal E2/NETA for the Treatment of Female Sexual Dysfunction in Naturally Menopausal Women: Results of a Randomized Active-Controlled Trial. The Journal of Sexual Medicine 2008;5(3):646-56
   PubMedGoogle Scholar
• Morris EP, Wilson PO, Robinson J, Long term effects of tibolone on the genital tract in postmenopausal women. Br J Obstet Gynaecol 1999;106(9):954
   PubMedGoogle Scholar
• Cummings SR, Ettinger B, Delmas PD, The Effects of Tibolone in Older Postmenopausal Women. New England Journal of Medicine 2008;359(7):697-708
   PubMed Web of Science ®Google Scholar
• Panjari M, Davis SR. DHEA therapy for women: effect on sexual function and wellbeing. Hum Reprod Update 2007;13(3):239-48
   PubMed Web of Science ®Google Scholar
• Kritz-Silverstein D, von Muhlen D, Laughlin GA, Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well-Ness (DAWN) Trial. J Am Geriatr Soc 2008;56(7):1292-8
   PubMed Web of Science ®Google Scholar
• Morales AJ, Nolan JJ, Nelson JC, Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.[erratum appears in. J Clin Endocrinol Metab 1995;Sep80(9):2799. Journal of Clinical Endocrinology & Metabolism 1994;78(6):1360-7
   Google Scholar
• Mortola JF, Yen SS. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 1990;71(3):696-704
   PubMedGoogle Scholar
• Labrie F, Archer D, Bouchard C, Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009;16(5):923-31
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C, Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009;16(5):907-22
   PubMed Web of Science ®Google Scholar
• Labrie F, Diamond P, Cusan L, Effect of 12-Month Dehydroepiandrosterone Replacement Therapy on Bone, Vagina, and Endometrium in Postmenopausal Women. J Clin Endocrinol Metab 1997;82(10):3498-505
   PubMed Web of Science ®Google Scholar
• Borsini F, Evans K, Jason K, Pharmacology of flibanserin. CNS Drug Rev 2002;8(2):117-42
   PubMedGoogle Scholar
• Marazziti D, Palego L, Giromella A, Region-dependent effects of flibanserin and buspirone on adenylyl cyclase activity in the human brain. Int J Neuropsychopharmacol 2002;5(02):131-40
   PubMedGoogle Scholar
• Allers KA, Dremencov E, Ceci A, ORIGINAL RESEARCH—BASIC SCIENCE: acute and Repeated Flibanserin Administration in Female Rats Modulates Monoamines Differentially Across Brain Areas: A Microdialysis Study. J Sex Med 2010;7(5):1757-67
   PubMedGoogle Scholar
• DeRogatis LR, Komer L, Katz M, Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women: efficacy of Flibanserin in the VIOLET Study. J Sex Med 2012;9(4):1074-85
   PubMed Web of Science ®Google Scholar
• Thorp J, Simon J, Dattani D, Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women: efficacy of Flibanserin in the DAISY Study. J Sex Med 2012;9(3):793-804
   PubMed Web of Science ®Google Scholar
• Nappi R, Dean J, van Lunsen R, Efficacy of continued flibanserin as a potential treatment for hypoactive sexual desire disorder in European premenopausal women:results from the ORCHID trial. J Sex Med 2009;6(Supp 5):409
   Google Scholar
• Goldfischer E, Cotton D, Mikl J, Efficacy of continued flibanserin treatment on sexual desire and satisfying sexual events in premenopausal women with HSDD: results form the ROSE study. J Sex Med 2008;5(Suppl 3):159
   Google Scholar
• Goldfischer E, Cotton D, Mikl J, Efficacy of continued flibanserin treatment on distress associated with sexual dysfunction in premenoapusal women with HSDD:: results form the ROSE study. J Sex Med 2008;5(Suppl 3):174
   Google Scholar
• Burnett AL, Calvin DC, Silver RI, Immunohistochemical Description of Nitric Oxide Synthase Isoforms in Human Clitoris. J Urol 1997;158(1):75-8
   PubMedGoogle Scholar
• Sipski ML, Rosen RC, Alexander CJ, Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injury. Urology 2000;55(6):812-15
   PubMedGoogle Scholar
• Fava M, Rankin MA, Alpert JE, An open trial of oral sildenafilin antidepressant-induced sexual dysfunction. Psychother Psychosom 1998;67(6):328-31
   PubMed Web of Science ®Google Scholar
• Caruso S, Intelisano G, Lupo L, Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. BJOG: An International Journal of Obstetrics & Gynaecology 2001;108(6):623-8
   PubMedGoogle Scholar
• Nurnberg HG, Hensley PL, Heiman JR, Sildenafil Treatment of Women With Antidepressant-Associated Sexual Dysfunction: a Randomized Controlled Trial. JAMA 2008;300(4):395-404
   PubMed Web of Science ®Google Scholar
• Basson R, McInnes R, Smith MD, Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002;11(4):367-77
   PubMedGoogle Scholar
• Basson R, Brotto LA. Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomised controlled trial. BJOG 2003;110(11):1014-24
   PubMed Web of Science ®Google Scholar
• Berman JR, Berman LA, Toler SM, Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. J Urol 2003;170(6 Pt 1):2333-8
   PubMedGoogle Scholar
• Leddy LS, Yang CC, Stuckey BG, Influence of Sildenafil on Genital Engorgement in Women with Female Sexual Arousal Disorder. J Sex Med 2012. [Epub ahead of print]
   PubMedGoogle Scholar
• Brown DA, Kyle JA, Ferrill MJ. Assessing the Clinical Efficacy of Sildenafil for the Treatment of Female Sexual Dysfunction. Ann Pharmacother 2009;43(7):1275-85
   PubMedGoogle Scholar
• Caruso S, Rugolo S, Agnello C, Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study. Fertil Steril 2006;85(5):1496-501
   PubMedGoogle Scholar
• DasGupta R, Wiseman OJ, Kanabar G, Efficacy of Sildenafil in the Treatment of Female Sexual Dysfunction Due to Multiple Sclerosis. J Urol 2004;171(3):1189-93
   PubMed Web of Science ®Google Scholar
• Pfaus J, Giuliano F, Gelez H. Bremelanotide: an Overview of Preclinical CNS Effects on Female Sexual Function. The Journal of Sexual Medicine 2007;4:269-79
   PubMedGoogle Scholar
• Diamond LE, Earle DC, Heiman JR, ORIGINAL RESEARCH—WOMEN'S SEXUAL HEALTH: an Effect on the Subjective Sexual Response in Premenopausal Women with Sexual Arousal Disorder by Bremelanotide (PT-141), a Melanocortin Receptor Agonist. J Sex Med 2006;3(4):628-38
   PubMed Web of Science ®Google Scholar
• Safarinejad MR. Evaluation of the Safety and Efficacy of Bremelanotide, a Melanocortin Receptor Agonist, in Female Subjects with Arousal Disorder: a Double-Blind Placebo-Controlled, Fixed Dose, Randomized Study. J Sex Med 2008;5(4):887-97
   PubMed Web of Science ®Google Scholar
• Rosen RC, Phillips NA, Gendrano NC, Oral phentolamine and female sexual arousal disorder: a pilot study. J Sex Marital Ther 1999;25(2):137-44
   PubMed Web of Science ®Google Scholar
• Kielbasa LA, Daniel KL. Topical Alprostadil Treatment of Female Sexual Arousal Disorder. Ann Pharmacother 2006;40(7):1369-76
   PubMedGoogle Scholar
• Islam A, Mitchel J, Rosen R, Topical Alprostadil in the Treatment of Female Sexual Arousal Disorder: a Pilot Study. J Sex Marital Ther 2001;27(5):531-40
   PubMed Web of Science ®Google Scholar
• Liao Q, Zhang M, Geng L, Efficacy and Safety of Alprostadil Cream for the Treatment of Female Sexual Arousal Disorder: a Double-Blind, Placebo-Controlled Study in Chinese Population. J Sex Med 2008;5(8):1923-31
   PubMedGoogle Scholar
• Lee H-J, Macbeth AH, Pagani JH, Oxytocin: the great facilitator of life. Prog Neurobiol 2009;88(2):127-51
   PubMed Web of Science ®Google Scholar
• CARMICHAEL MS, HUMBERT R, DIXEN J, Plasma Oxytocin Increases in the Human Sexual Response. J Clin Endocrinol Metab 1987;64(1):27-31
   PubMed Web of Science ®Google Scholar
• Burri A, Heinrichs M, Schedlowski M, The acute effects of intranasal oxytocin administration on endocrine and sexual function in males. Psychoneuroendocrinology 2008;33(5):591-600
   PubMed Web of Science ®Google Scholar
• Dhillon S, Yang LPH, Curran MP. Bupropion: a Review of its Use in the Management of Major Depressive Disorder. Drugs 2008;68(5):653-89
   PubMed Web of Science ®Google Scholar
• Moll JL, Brown CS. The Use of Monoamine Pharmacological Agents in the Treatment of Sexual Dysfunction: evidence in the Literature. The Journal of Sexual Medicine 2011;8(4):956-70
   PubMedGoogle Scholar
• Ito TY, Polan ML, Whipple B, The Enhancement of Female Sexual Function with ArginMax, a Nutritional Supplement, Among Women Differing in Menopausal Status. Journal of sex & marital therapy 2006;32(5):369-78
   PubMed Web of Science ®Google Scholar
• Both S, Everaerd W, Laan E, Effect of a Single Dose of Levodopa on Sexual Response in Men and Women. Neuropsychopharmacology 2004;30(1):173-83
   Google Scholar
• Shamloul R. Natural Aphrodisiacs. The Journal of Sexual Medicine 2010;7(1pt1):39-49
   PubMedGoogle Scholar
• Groysman V. Vulvodynia: new Concepts and Review of the Literature. Dermatol Clin 2010;28(4):681-96
   PubMed Web of Science ®Google Scholar
• Andrews JCMDF. Vulvodynia Interventions-Systematic Review and Evidence Grading. Obstetrical & Gynecological Survey 2011;66(5):299-315
   PubMedGoogle Scholar
• Pagano R, Wong S. Use of Amitriptyline Cream in the Management of Entry Dyspareunia Due to Provoked Vestibulodynia. J Low Genit Tract Dis 2012; [Epub ahead of print]
   PubMedGoogle Scholar
• Damsted-Petersen C, Boyer SC, Pukall CF. Current perspectives in vulvodynia. Women's Health 2009;5(4):423-36
   PubMedGoogle Scholar
• Snabes M, Simes S. Testosterone to treat hypoactive sexual desire disorder (HSDD) in women: the need for an approved product is greater than ever. Program of ISSWSH, Florence 2009(Poster 10): p. 15
   Google Scholar